[go: up one dir, main page]

WO1999057241A3 - Myelin basic protein peptides and uses thereof - Google Patents

Myelin basic protein peptides and uses thereof Download PDF

Info

Publication number
WO1999057241A3
WO1999057241A3 PCT/US1999/009930 US9909930W WO9957241A3 WO 1999057241 A3 WO1999057241 A3 WO 1999057241A3 US 9909930 W US9909930 W US 9909930W WO 9957241 A3 WO9957241 A3 WO 9957241A3
Authority
WO
WIPO (PCT)
Prior art keywords
basic protein
myelin basic
protein peptides
invention pertains
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/009930
Other languages
French (fr)
Other versions
WO1999057241A9 (en
WO1999057241A2 (en
Inventor
Subhashini Arimilli
Shrikant Deshpande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ507901A priority Critical patent/NZ507901A/en
Priority to AU37890/99A priority patent/AU3789099A/en
Priority to JP2000547197A priority patent/JP2002513558A/en
Priority to EP99920379A priority patent/EP1080185A4/en
Priority to CA002330826A priority patent/CA2330826A1/en
Priority to HK02101092.3A priority patent/HK1039636A1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of WO1999057241A2 publication Critical patent/WO1999057241A2/en
Publication of WO1999057241A3 publication Critical patent/WO1999057241A3/en
Publication of WO1999057241A9 publication Critical patent/WO1999057241A9/en
Priority to NO20005547A priority patent/NO20005547L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention pertains generally to the treatment of autoimmune diseases of the central nervous system characterized by demyelination. In particular, this invention pertains to novel peptides derived from human myelin basic protein (MBP). When complexed with the appropriate major histocompatibility complex (MHC) molecule, these peptides can be used to treat multiple sclerosis and other demyelinating autoimmune diseases.
PCT/US1999/009930 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof Ceased WO1999057241A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU37890/99A AU3789099A (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof
JP2000547197A JP2002513558A (en) 1998-05-05 1999-05-05 Myelin basic protein peptide and use thereof
EP99920379A EP1080185A4 (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof
CA002330826A CA2330826A1 (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof
HK02101092.3A HK1039636A1 (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof
NZ507901A NZ507901A (en) 1998-05-05 1999-05-05 Isolated myelin basic protein (MBP) for treating mutliple sclerosis
NO20005547A NO20005547L (en) 1998-05-05 2000-11-03 Myelin base protein peptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7310998A 1998-05-05 1998-05-05
US09/073,109 1998-05-05

Publications (3)

Publication Number Publication Date
WO1999057241A2 WO1999057241A2 (en) 1999-11-11
WO1999057241A3 true WO1999057241A3 (en) 2000-01-13
WO1999057241A9 WO1999057241A9 (en) 2000-02-17

Family

ID=22111789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009930 Ceased WO1999057241A2 (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof

Country Status (10)

Country Link
EP (1) EP1080185A4 (en)
JP (1) JP2002513558A (en)
CN (1) CN1308671A (en)
AU (1) AU3789099A (en)
CA (1) CA2330826A1 (en)
HK (1) HK1039636A1 (en)
NO (1) NO20005547L (en)
NZ (1) NZ507901A (en)
WO (1) WO1999057241A2 (en)
ZA (1) ZA200006268B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002088317A2 (en) * 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
ITFI20010114A1 (en) 2001-06-22 2002-12-22 Univ Firenze GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE IN THE DIAGNOSIS OR THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
AU2008327638A1 (en) * 2007-11-20 2009-05-28 Eldrug S.A. Peptide analogues and conjugates thereof
CA2981422A1 (en) * 2015-03-30 2016-10-06 Osaka University Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disease containing same, and method for treating immune disease
WO2020257221A1 (en) * 2019-06-18 2020-12-24 The Scripps Research Institute Methods and compositions for treating inflammatory conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040944A2 (en) * 1995-06-07 1996-12-19 Zymogenetics, Inc. Fused soluble mhc heterodimer:peptide complexes and their uses
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
WO1996040944A2 (en) * 1995-06-07 1996-12-19 Zymogenetics, Inc. Fused soluble mhc heterodimer:peptide complexes and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAG B., ET AL.: "FUNCTIONALLY ACTIVE RECOMBINANT ALPHA AND BETA CHAIN-PEPTIDE COMPLEXES OF HUMAN MAJOR HISTOCOMPATIBILITY CLASS II MOLECULES.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271., no. 17., 26 April 1996 (1996-04-26), US, pages 10413 - 10418., XP002922540, ISSN: 0021-9258, DOI: 10.1074/jbc.271.17.10413 *
See also references of EP1080185A4 *

Also Published As

Publication number Publication date
ZA200006268B (en) 2001-08-22
CN1308671A (en) 2001-08-15
HK1039636A1 (en) 2002-05-03
AU3789099A (en) 1999-11-23
WO1999057241A9 (en) 2000-02-17
CA2330826A1 (en) 1999-11-11
WO1999057241A2 (en) 1999-11-11
NO20005547L (en) 2001-01-02
NO20005547D0 (en) 2000-11-03
EP1080185A4 (en) 2005-01-26
NZ507901A (en) 2003-06-30
JP2002513558A (en) 2002-05-14
EP1080185A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
SI1918298T1 (en) Peptide
WO1996034953A3 (en) Cd16-ii variants
AU3368497A (en) Human dnase i hyperactive variants
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
GB2367061A (en) Peptides
WO2002036614A3 (en) Peptides for use in the treatment of alzheimer's disease
WO1999059617A3 (en) Immunoregulator
WO1995006727A3 (en) Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1999057241A3 (en) Myelin basic protein peptides and uses thereof
WO1998011234A3 (en) Human protein kinases
IL143516A (en) E3 ubiquitin ligase polypeptide, polynucleotide encoding the same and uses thereof
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
ZA961628B (en) Diagnostic method test kit drug and therapeutic treatment for autoimmune diseases
ZA961419B (en) Human DNase I variants.
AU2003208197A1 (en) Use of soluble fgl2 as an immunosuppressant
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
TR199700842T1 (en) �nsan DNase I Varyantlar�.
WO2002081508A3 (en) Use of cd25 binding molecules in steroid-resistant patients
EP0780472A3 (en) Stress proteins
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
WO1998036758A3 (en) Therapeutic agents containing oxygen anion radicals and the use thereof in the treatment of parkinson's disease
MXPA03000980A (en) C3b/c4b complement receptor-like molecules and uses thereof.
AU3846297A (en) Use of recombinant myelin protein for treating t-cell-mediated autoimmune diseases of the peripheral nervous system

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808248.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2330826

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/010759

Country of ref document: MX

Ref document number: 507901

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000/06268

Country of ref document: ZA

Ref document number: 200006268

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 547197

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 37890/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999920379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999920379

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999920379

Country of ref document: EP